Vascular endothelial growth factor in thyroid cancers.

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• Vascular endothelial growth factor (VEGF) is crucial for physiological and pathological angiogenesis, including tumor growth and metastasis.
• VEGF exhibits alternative splicing, producing various isoforms (VEGF121, VEGF165, VEGF189, VEGF206).
• VEGF signaling involves tyrosine kinase receptors like fms-like tyrosine kinase (FLT), regulating blood vessel development.

Purpose of the Study:

• To investigate the structure, receptors, and role of VEGF in tumor angiogenesis, with a specific focus on thyroid cancer.
• To understand the mechanisms of VEGF regulation, including hypoxia-dependent and -independent pathways.
• To explore the clinical applications of VEGF in cancer diagnosis, prognosis, and treatment.

Main Methods:

• Purification of VEGF from A-431 cells and detection of VEGF-binding sites on endothelial cells.
• Affinity cross-linking to identify VEGF-binding polypeptides.
• Analysis of VEGF mRNA isoforms and receptor tyrosine kinases (FLT).

Main Results:

• VEGF-binding complexes of 230, 170, and 125 kDa were identified on endothelial cells.
• VEGF induced tyrosine phosphorylation of a 190-kDa polypeptide, a key component of the VEGF receptor complex.
• VEGF regulation involves complex mechanisms, with hypoxia potentially increasing VEGF transcription in tumor cells.

Conclusions:

• VEGF plays a significant role in thyroid cancer angiogenesis.
• Anti-angiogenesis therapy targeting VEGF presents a viable treatment strategy for thyroid cancer.
• Further research into anti-VEGF therapies and vaccines is warranted for advanced thyroid cancer and high-risk patients.